<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716806</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-015</org_study_id>
    <nct_id>NCT01716806</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)</brief_title>
  <official_title>A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study brentuximab vedotin to find out whether it is an effective treatment
      for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study
      will be older or will have other conditions that make them unable to have standard
      chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with
      other drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as
      monotherapy and in combination with other agents as frontline therapy. There are 6 parts of
      the study. The population to be studied includes treatment-naïve patients with classical
      Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell
      lymphoma (PTCL).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2012</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with complete response (CR) or (PR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR according to modified Lugano criteria per blinded independent central review (BICR) (Parts E and F)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only); up to approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose of brentuximab vedotin (all parts) or through 100 days after last dose of nivolumab (Part D only); up to approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of the first documentation of complete tumor response (CR) to the first documentation of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the time from start of study treatment to first documentation of tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to approximately 10 years</time_frame>
    <description>Defined as the proportion of patients with CR, PR, or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR according to Lugano criteria per BICR (Parts E and F)</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B symptom resolution rate</measure>
    <time_frame>Through 1 month following last dose; up to approximately 16 months</time_frame>
    <description>Defined as the proportion of patients with lymphoma-related B symptoms at baseline who achieve resolution of all B symptoms at any time during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of brentuximab vedotin</measure>
    <time_frame>Up to approximately 16 months. Cycle 1: predose, 30 minutes, and 24, 48, 168, and 336 hours post-dose; Cycles 2 and later (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of brentuximab vedotin antitherapeutic antibodies (ATA)</measure>
    <time_frame>Up to approximately 18 months. Cycles 1, 2, 4, and every 4 cycles thereafter (through 1 month post last dose [Parts A, B, and C] or through 100 days post last dose of nivolumab [Part D only]): predose</time_frame>
    <description>Defined as the proportion of patients who develop ATA to brentuximab vedotin at any time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of nivolumab (Part D only)</measure>
    <time_frame>Up to approximately 16 months. Cycle 1: predose, 30 minutes, and 168 and 336 hours post-dose; Cycles 2, 4, and every 4 cycles thereafter (through 1 month post last dose): pre-dose and 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nivolumab antitherapeutic antibodies (ATA) (Part D only)</measure>
    <time_frame>Up to approximately 18 months. Cycles 1, 2, 4, and every 4 cycles thereafter (through 100 days post last dose of nivolumab): predose</time_frame>
    <description>Defined as the proportion of patients who develop ATA to nivolumab at any time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Parts E and F only)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Defined as the time from start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part A: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F: Brentuximab Vedotin in PTCL Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Part A: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
    <arm_group_label>Part E: Brentuximab Vedotin in HL Patients</arm_group_label>
    <arm_group_label>Part F: Brentuximab Vedotin in PTCL Patients</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>70 mg/m^2 by IV infusion on Days 1 and 2 of 3-week cycle</description>
    <arm_group_label>Part C: Brentuximab Vedotin + Bendamustine in HL Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>375 mg/m^2 every 3 weeks by IV infusion</description>
    <arm_group_label>Part B: Brentuximab Vedotin + Dacarbazine in HL Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>3 mg/kg every 3 weeks by IV infusion</description>
    <arm_group_label>Part D: Brentuximab Vedotin + Nivolumab in HL Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parts A, B, C, and D: 60 years of age or older

          -  Treatment-naive patients with histopathological diagnosis of classical Hodgkin
             lymphoma (Parts A, B, C, D, and E)

          -  Treatment-naive patients with CD30-expressing PTCL (Part F)

          -  Ineligible for or have declined initial conventional combination chemotherapy for HL
             (Parts A, B, C, and D)

          -  Unsuitable or unfit for initial conventional combination chemotherapy for HL (Part E)
             or CD30-expressing PTCL due to the presence of comorbidity-factors, as documented by:

               -  A CIRS score of 10 or greater

               -  Requiring assistance with or dependence on other for any instrumental activities
                  of daily living (IADLs)

          -  Measurable disease of at least 1.5 cm as documented by radiographic technique

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3
             (Parts, A, B, C, E, and F) or less than or equal to 2 (Part D)

        Exclusion Criteria:

          -  Symptomatic neurologic disease compromising IADLs or requiring medication

          -  History of progressive multifocal leukoencephalopathy

          -  Grade 3 or higher viral, bacterial, or fungal infection within 2 weeks prior to the
             first dose of brentuximab vedotin

          -  Concurrent use of other investigational agents

          -  Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not
             completed 4 weeks prior to first dose of study drug

          -  History of another malignancy within 1 year before first dose of study drug (Parts E
             and F only)

          -  Part D only:

               -  Received any prior immune-oncology therapy

               -  History of known or suspected autoimmune disease

               -  Prior allogeneic stem cell transplant

               -  History of cerebral vascular event within 6 months of first dose of study drug

               -  Active interstitial lung disease that is symptomatic or may interfere with the
                  detection or management of suspected drug-related pulmonary toxicology

               -  Known history of pancreatitis

          -  Parts D, E, and F only:

               -  Known cerebral/meningeal disease related to the underlying malignancy

               -  Systemic treatment with corticosteroids or other immunosuppressive medications
                  within 1 week of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sims, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitkumar Mehta</last_name>
      <phone>205-996-8400</phone>
      <email>anmehta@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melonie Hupp</last_name>
      <phone>205-975-2944</phone>
      <email>mjwest@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amitkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Alabama - Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Rodgers</last_name>
      <phone>251-445-8427</phone>
      <email>lrodgers@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Omar Alkharabsheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alaska Urological Institute</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Bergelin</last_name>
      <phone>480-256-5168</phone>
      <email>Jana.bergelin@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Javier Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Donald Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center / University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lora Inclan</last_name>
      <phone>520-694-9053</phone>
      <email>linclan@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Persky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Sullivan</last_name>
      <phone>479-695-4168</phone>
      <email>msullivan@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>J. Thaddeus Beck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anneliese Cadena</last_name>
      <phone>818-748-4797</phone>
      <email>Anneliese.cadena@providence.org</email>
    </contact>
    <investigator>
      <last_name>Raul Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Romero</last_name>
      <phone>626-256-4673</phone>
      <email>andromero@coh.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Mei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>John Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Wicker</last_name>
      <phone>888-737-7408</phone>
      <email>hwicker@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists / Northside Hospital Cancer Institute</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duane Stallings</last_name>
      <phone>770-496-9400</phone>
      <email>duane.stallings@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Veum</last_name>
      <phone>312-563-3710</phone>
      <email>Simone_p_veum@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Seo-Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists / Advocate Lutheran General Hospital</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, P.A.</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cipriano</last_name>
      <phone>301-571-2016</phone>
      <email>jcipriano@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Davis</last_name>
      <phone>313-576-9370</phone>
      <email>davisv@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Erlene Seymour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Vincent</last_name>
      <phone>702-952-3400</phone>
      <email>Trisha.Vincent@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey / Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903-2681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Merz</last_name>
      <phone>732-235-2465</phone>
      <email>mm2778@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Evens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Garbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center / University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista French</last_name>
      <phone>585-275-4911</phone>
      <email>Krista_French@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Friedberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>James Essell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital / Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoof Giali</last_name>
      <phone>614-293-5655</phone>
      <email>Raoof.Giali@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Brammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Yasenchak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Spencer Shao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health-Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Cancer Center</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Arant-Daigle</last_name>
      <phone>817-261-4906</phone>
      <email>deborah.arant-daigle@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Scott Fleischauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Henrik Illum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Ford</last_name>
      <phone>214-346-3517</phone>
      <email>Lindsay.Ford@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristi McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton South</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Charles Kurkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Robert Ruxer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Matei Socoteanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Seton Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Vivian Cline-Burkhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Jerome Goldschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Dipti Patel-Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Lantis</last_name>
      <phone>804-828-2177</phone>
      <email>kllantis@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Yazbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pagel</last_name>
      <phone>206-215-1426</phone>
      <email>john.pagel@swedish.org</email>
    </contact>
    <investigator>
      <last_name>John Pagel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariah Endres</last_name>
      <phone>608-263-1836</phone>
      <email>maendres3@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Chris Fletcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>monomethylauristatin E</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>CD30-expression</keyword>
  <keyword>PTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

